Curaleaf Holdings, Inc. (CNSX:CURA) signed a definitive agreement to acquire Emmac Life Sciences Limited for approximately £260 million on March 9, 2021. Curaleaf Holdings, Inc. will pay approximately £35 million in cash and approximately 17.5 million subordinate voting shares of Curaleaf Holdings, Inc. An additional of £7.2 million consideration will be paid in cash and £34 million in shares which is subject to performance-based earn-outs. The transaction s subjected to regulatory approval and customary closing conditions. The transaction has been unanimously approved by Board of Directors of Curaleaf Holdings, Inc. and Emmac Life Sciences Limited. Special Committee is formed composed of members of the board of directors of Curaleaf Holdings, Inc. The transaction is expected to close in second quarter of 2021. Stikeman Elliott LLP and Memery Crystal LLP acted as legal advisor to Curaleaf Holdings, Inc. Canaccord Genuity Group Inc. (TSX:CF) acted as financial advisor and provided fairness opinion to Emmac Life Sciences Limited. Norton Rose Fulbright US LLP and Hill Dickinson LLP acted as legal advisor to Emmac Life Sciences Limited. Eight Capital acted as financial advisor and provided a fairness opinion to the Special Committee of Curaleaf Holdings, Inc. Curaleaf Holdings, Inc. (CNSX:CURA) completed the acquisition of Emmac Life Sciences Limited on April 7, 2021. Curaleaf Holdings secured an investment of $130 million (£93.5662 million) from a single strategic institutional investor in exchange for 31.5% equity stake in Curaleaf International. The subscription funded the entire cash portion of the EMMAC acquisition cash consideration of $50 million (£35.987 million). Following the successful completion of the transaction, Antonio Costanzo has been appointed as the new Chief Executive Officer of Curaleaf International, with the former EMMAC management team continuing to lead Curaleaf's new European presence as well as driving local European strategy and day-to-day operations.